Silencing of the transcriptional factor ZEB1 alters the steroidogenic pathway, and increases the concentration of testosterone and DHT in DU145 cells

Herrera,D.; Orellana‑Serradell,O.; Villar,P.; Torres,M. J.; Paciucci,R.; Castellón,E. A.; Contreras,H. R.

doi:10.3892/or.2018.6885

Silencing of the transcriptional factor ZEB1 alters the steroidogenic pathway, and increases the concentration of testosterone and DHT in DU145 cells

Authors:
- D. Herrera
- O. Orellana‑Serradell
- P. Villar
- M. J. Torres
- R. Paciucci
- E. A. Castellón
- H. R. Contreras
View Affiliations

Affiliations: Department of Basic and Clinic Oncology, Faculty of Medicine, University of Chile, 8380453 Santiago, Chile, Biomedical Research Group of Urology, Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain
Published online on: November 26, 2018 https://doi.org/10.3892/or.2018.6885
Pages: 1275-1283

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Prostate cancer (PCa) is the second most common type of male malignancy worldwide. The transcription factor zinc finger E‑box binding homeobox 1 (ZEB1) is associated with epithelial‑mesenchymal transition and is also involved in regulation of androgen receptor (AR) expression, the main ligands of which are testosterone and dihydrotestosterone (DHT). These androgens are synthesized through the steroidogenic pathway within the prostate, and their synthesis is altered in PCa. The present study aimed to determine the ZEB1‑induced alterations in androgen synthesis and AR expression in the DU145 PCa cell line. Reverse transcription‑quantitative polymerase chain reaction, western blotting and immunocytochemistry were used to determine the mRNA and protein expression levels, and cellular localization of steroidogenic pathway enzymes in the DU145 cell line in response to ZEB1 silencing. Furthermore, the concentrations of testosterone and DHT were detected in cell culture medium using ELISA. ZEB1‑silenced cells exhibited an increase in testosterone and DHT production, an increase in AR expression and an alteration in the steroidogenic pathway. In particular, steroidogenic acute regulatory protein and 5α‑reductase 2 expression levels were decreased, whereas cytochrome P450 family 17 subfamily A member 1, 5α‑reductase 1, aldo‑keto reductase family 1 member D1 and aldo‑keto reductase family 1 member C2 expression levels were increased. In conclusion, the present study provided novel information regarding the regulation of intratumoral androgen production in PCa, which is relevant for the progression of the disease to a castration‑resistant form.

View Figures

View References

1	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018. View Article : Google Scholar : PubMed/NCBI
2	Anantharaman A and Frieddlaner TW: Targeting the androgen receptor in metastatic castrate-resistant prostate cancer: A review. Urol Oncol. 34:356–367. 2016. View Article : Google Scholar : PubMed/NCBI
3	Lonergan PE and Tindall DJ: Androgen receptor signaling in prostate cancer development and progression. J Carcinog. 10:202011. View Article : Google Scholar : PubMed/NCBI
4	Chandrasekar T, Yang JC, Gao AC and Evans CP: Mechanisms of resistance in castration-resistant prostate cancer (CRPC). Transl Androl Urol. 4:365–380. 2015.PubMed/NCBI
5	Mitsiades N, Sung C, Schultz N, Danila DC, He B, Eedunuri VK, Fleisher M, Sander C, Sawyers CL and Scher HI: Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors. Cancer Res. 72:6142–6152. 2012. View Article : Google Scholar : PubMed/NCBI
6	Banerjee P, Banerjee S, Brown T and Zirkin B: Androgen action in prostate function and disease. Am J Clin Exp Urol. 6:62–77. 2018.PubMed/NCBI
7	Sun Y, Wang BE, Leong KG, Yue P, Li L, Jhunjhunwala S, Chen D, Seo K, Modrusan Z, Gao WQ, et al: Androgen deprivation causes epithelial-mesenchymal transition in the prostate: Implications for androgen-deprivation therapy. Cancer Res. 72:527–536. 2012. View Article : Google Scholar : PubMed/NCBI
8	Anose BM and Sanders MM: Androgen receptor regulates transcription of the ZEB1 transcription factor. Int J Endocrinol. 2011:9039182011. View Article : Google Scholar : PubMed/NCBI
9	Orellana-Serradell O, Herrera D, Castellon E and Contreras HR: The transcription factor ZEB1 promotes an aggressive phenotype in prostate cancer cell lines. Asian J Androl. 20:294–299. 2018. View Article : Google Scholar : PubMed/NCBI
10	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
11	Payne AH and Hales DB: Overview of steroidogenic enzymes in the pathway from cholesterol to active steroid hormones. Endocr Rev. 25:947–970. 2004. View Article : Google Scholar : PubMed/NCBI
12	Mostaghel EA: Steroid hormone synthetic pathways in prostate cancer. Transl Androl Urol. 2:212–227. 2013.PubMed/NCBI
13	Chen M and Penning TM: 5β-Reduced steroids and human Δ4-3-ketosteroid 5β-reductase (AKR1D1). Steroids. 83:17–26. 2014. View Article : Google Scholar : PubMed/NCBI
14	Zeng CM, Chang LL, Ying MD, Cao J, He QJ, Zhu H and Yang B: Aldo-keto reductase AKR1C1-AKR1C4: Functions, regulation, and intervention for anti-cancer therapy. Front Pharmacol. 8:1192017. View Article : Google Scholar : PubMed/NCBI
15	Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, True LD and Nelson PS: Maintenance of intratumoral androgens in metastatic prostate cancer: A mechanism for castration-resistant tumor growth. Cancer Res. 68:4447–4454. 2008. View Article : Google Scholar : PubMed/NCBI
16	Rizner TL, Lin HK, Peehl DM, Steckelbroeck S, Bauman DR and Penning TM: Human type 3 3alpha-hydroxysteroid dehydrogenase (aldo-keto reductase 1 C2) and androgen metabolism in prostate cells. Endocrinology. 144:2922–2932. 2003. View Article : Google Scholar : PubMed/NCBI
17	Basu S and Tindall DJ: Androgen action in prostate cancer. Horm Cancer. 1:223–228. 2010. View Article : Google Scholar : PubMed/NCBI
18	Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, et al: Integrative genomic profiling of human prostate cancer. Cancer Cell. 18:11–22. 2010. View Article : Google Scholar : PubMed/NCBI
19	Zhang A, Zhang J, Plymate S and Mostaghel EA: Classical and non-classical roles for pre-receptor control of DHT metabolism in prostate cancer progression. Horm Cancer. 7:104–113. 2016. View Article : Google Scholar : PubMed/NCBI
20	Huang KH, Chiou SH, Chow KC, Lin TY, Chang HW, Chiang IP and Lee MC: Overexpression of aldo-keto reductase 1C2 is associated with disease progression in patients with prostatic cancer. Histopathology. 57:384–394. 2010. View Article : Google Scholar : PubMed/NCBI
21	Ji Q, Chang L, VanDenBerg D, Stanczyk FZ and Stolz A: Selective reduction of AKR1C2 in prostate cancer and its role in DHT metabolism. Prostate. 54:275–289. 2003. View Article : Google Scholar : PubMed/NCBI
22	Kobayashi T, Inoue T, Kamba T and Ogawa O: Experimental evidence of persistent androgen-receptor-dependency in castration-resistant prostate cancer. Int J Mol Sci. 14:15615–15635. 2013. View Article : Google Scholar : PubMed/NCBI
23	Lubik A, Nouri M, Truong S, Ghaffari M, Adomat HH, Corey E, Cox ME, Li N, Guns ES, Yenki P, et al: Paracrine sonic hedgehog signaling contributes significantly to acquired steroidogenesis in the prostate tumor microenvironment. Int J Cancer. 140:358–369. 2017. View Article : Google Scholar : PubMed/NCBI
24	Audet-Walsh É, Yee T, Tam IS and Giguère V: Inverse regulation of DHT synthesis enzymes 5α-reductase types 1 and 2 by the androgen receptor in prostate cancer. Endocrinology. 158:1015–1021. 2017. View Article : Google Scholar : PubMed/NCBI
25	Locke JA, Guns ES, Lubik AA, Adomat HH, Hendy SC, Wood CA, Ettinger SL, Gleave ME and Nelson CC: Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res. 68:6407–6415. 2008. View Article : Google Scholar : PubMed/NCBI